Eli Lilly and Company $LLY is Atika Capital Management LLC's 6th Largest Position

Key Points

• Atika Capital Management LLC has increased its stake in Eli Lilly and Company by 1.4%, now owning 33,100 shares valued at approximately $27.34 million, making it the firm's sixth largest position.
• Eli Lilly recently reported earnings of $6.31 per share, significantly exceeding analysts' estimates, and announced a quarterly dividend of $1.50 per share, with a yield of 0.9%.
• Analysts have mixed views on Eli Lilly, with price targets varying from $825 to $950, but a consensus rating of "Moderate Buy" according to recent reports.

Atika Capital Management LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,100 shares of the company's stock after purchasing an additional 450 shares during the quarter. Eli Lilly and Company accounts for 3.8% of Atika Capital Management LLC's holdings, making the stock its 6th biggest holding. Atika Capital Management LLC's holdings in Eli Lilly and Company were worth $27,338,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Knightsbridge Asset Management LLC raised its position in Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock valued at $628,000 after purchasing an additional 15 shares during the last quarter. Corient IA LLC bought a new position in shares of Eli Lilly and Company during the first quarter worth about $570,000. LS Investment Advisors LLC raised its position in shares of Eli Lilly and Company by 1.7% during the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after acquiring an additional 40 shares during the last quarter. Prism Advisors Inc. bought a new position in shares of Eli Lilly and Company during the first quarter worth about $207,000. Finally, CSM Advisors LLC raised its position in shares of Eli Lilly and Company by 30.6% during the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after acquiring an additional 245 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger acquired 117 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David A. Ricks acquired 1,632 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock worth $2,894,841 in the last 90 days. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $0.9090 during mid-day trading on Friday, hitting $710.7290. The stock had a trading volume of 3,217,264 shares, compared to its average volume of 6,973,298. The firm has a market cap of $672.68 billion, a P/E ratio of 46.45, a PEG ratio of 0.99 and a beta of 0.44. The business has a fifty day moving average price of $754.70 and a 200-day moving average price of $790.90. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $972.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the company posted $3.92 EPS. The firm's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is presently 39.22%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. UBS Group lowered their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Cantor Fitzgerald lowered their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Leerink Partners restated a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price objective for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.